Unknown PHASE1 INTERVENTIONAL 1-arm NCT02345824

Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma

Early-Phase Study to Assess Tumor Pharmacokinetics and Efficacy of the CDK4/6 Inhibitor Ribociclib (LEE011) in Patients With Recurrent Glioblastoma or Anaplastic Glioma

Sponsor: Novartis Pharmaceuticals

Conditions Glioblastoma Glioma

Interventions Ribociclib

Updated 8 times since 2017 Last updated: Jun 5, 2018 Started: Mar 31, 2016 Primary completion: Sep 30, 2019 Completion: Jan 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Glioblastoma and Glioma, this trial is ongoing. The trial is conducted by Novartis Pharmaceuticals and has accumulated 8 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jul 2020 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Active Not Recruiting → Unknown Status
Jul 2018 — Jul 2020 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting

▶ Show 3 earlier versions

Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE1
Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals
University of Virginia

Data source: University of Virginia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Charlottesville, United States